跳至主要内容
临床试验/NCT06359834
NCT06359834招募中不适用

Comparison of Remimazolam and Propofol Effect on Oxygen Reserve During Endoscopic Retrograde Cholangiopancreatography

Yonsei University1 个研究点 分布在 1 个国家目标入组 112 人开始时间: 2024年4月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
112
试验地点
1
主要终点
Incidence of Oxygen Reserve Index (ORI) drop to 0.00 during sedation

研究概览

简要总结

Propofol is one of the most commonly used sedative in endoscopic procedures, while its potency to induce respiratory depression may threaten patient safety. Remimazolam is known to less likely induce hemodynamic instability when compared to propofol, yet its favorable effects are not clearly evaluated in endoscopic procedures. Hence, this study aimed to compare hemodynamic effects of remimazolam and propofol, by evaluating oxygen reserve index (ORI) in patients scheduled for endoscopic retrograde cholangiopancreatography.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients (age 19~80 yrs, ASA Class I~III) who are scheduled for elective endoscopic retrograde cholangiopancreatograph

排除标准

  • Pregnancy Allergy to remimazolam or propofol Underlying pulmonary diseases or obstructive sleep apnea Underlying renal (serum Cr >2mg/dL) or cardiac disease (NYHA class III or IV) Hypotension (SBP <90mmHg) or hypoxemia (SpO2 <90%) assessed prior to procedure

研究组 & 干预措施

Remimazolam

Experimental

Patient group who receives remimazolam for sedation during endoscopy

干预措施: Remimazolam besylate (Drug)

Propofol

Active Comparator

Patient group who receives propofol for sedation during endoscopy

干预措施: Propofol (Drug)

结局指标

主要结局

Incidence of Oxygen Reserve Index (ORI) drop to 0.00 during sedation

时间窗: Evaluation begins after sedative administration until the end of endoscopic procedure.

Incidence of Oxygen Reserve Index (ORI) drop to 0.00 will be evaluated after sedative administration, until the end of endoscopic procedure.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验